Maria Silva
Nurse Practitioner · Johnston, RINPI 1790818748
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 27.1% of the total. 2025 is the largest year on record at $1,942, more than ten times the $54 reported in 2021. Among nurse practitioner clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lundbeck LLC$1K
- Teva Pharmaceuticals USA, Inc.$733
- Biohaven Pharmaceutical Holding Company Ltd.$515
- Lilly USA, LLC$514
- Amgen$374
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,755100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 96 | $1,832 |
| Lundbeck LLC | 48 | $1,119 |
| Teva Pharmaceuticals USA, Inc. | 34 | $733 |
| Biohaven Pharmaceutical Holding Company Ltd. | 24 | $515 |
| Lilly USA, LLC | 27 | $514 |
| Amgen(2 entities) | 17 | $374 |
| SK Life Science, Inc. | 11 | $297 |
| EMD Serono, Inc. | 13 | $275 |
| Eisai Inc. | 7 | $192 |
| Sumitomo Pharma America, Inc. | 8 | $173 |
| Axsome Therapeutics, Inc. | 5 | $108 |
| UCB, Inc. | 4 | $94 |
| Sunovion Pharmaceuticals Inc. | 5 | $86 |
| Impel Pharmaceuticals Inc. | 4 | $75 |
| AstraZeneca | 3 | $63 |
| Biogen | 2 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| Upsher-smith Laboratories LLC | 2 | $37 |
| MDD US Operations, LLC | 1 | $31 |
| Neurelis, Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Life Molecular Imaging Ltd | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,755 in reported general payments places this provider in the 95th percentile of 396 nurse practitioner providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 69 | $55,195 |
| Nurtec OdtRimegepant Sulfate | 19 | $25,509 |
| UbrelvyUbrogepant | 26 | $23,730 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $20,994 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 18 | $18,045 |
| AptiomEslicarbazepine Acetate | 13 | $15,704 |
| QuliptaAtogepant | 14 | $14,129 |
| Lacosamide | 83 | $10,578 |
| Ajovy SyringeFremanezumab-Vfrm | 13 | $9,128 |
| Levetiracetam | 232 | $8,927 |
| Topiramate | 192 | $2,358 |
| Memantine Hcl ErMemantine Hcl | 20 | $2,105 |
| Primidone | 38 | $1,768 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 56 | $1,663 |
| Oxcarbazepine | 51 | $1,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $1,832 | $37,85940 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $86 | $15,70413 claims |
| Upsher-smith Laboratories LLCTopiramate | $37 | $2,358192 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 396 nurse practitioner providers in Rhode Island.
Other nurse practitioner in Johnston
- Stephanie DemelloJohnston$967
- Mohini YalanisJohnston$822
- Linda YoungLincoln$19K
- Lynne GlaserCumberland$17K
- Stephanie CostaWarwick$9K
- Natalie DriscollMiddletown$6K
- Lea KellyProvidence$5K
- Kathleen ParkerWarwick$5K
- Priscilla PonteEast Providence$5K
- Jennifer JohnsonNarragansett$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.